Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Publication|Articles|November 20, 2024
- November 2024
- Volume 30
- Issue 12
- Pages: SP952-SP956
As Myeloma Trials Tackle Frontline Treatment, Where Are the Black Patients?
Author(s)Ryan Flinn, Mary Caffrey
Advertisement
Advertisement
The recent FDA approval in multiple myeloma of isatuximab (Sarclisa; Sanofi) marked a significant advance for patients newly diagnosed with the disease. When added to the triplet of bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd), the combination reduced the risk of disease progression and death by 40% compared with the VRd triplet alone for patients who cannot receive a transplant.1
Related to this article
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
This week in health equity and access: PMOS diagnosis, HIV lung cancer screening, transplant access, atopic dermatitis care, and value-based oncology.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.
Among people with HIV, lung cancer screening eligibility rose from 6% to 15% in 6 years, but uptake stayed under 30%.
Advertisement
Advertisement